You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

480 Results
Document
Oct 2019
Blog post
Dr. Edward Kucharski Among the many healthcare challenges facing trans and non-binary people, cancer poses a multi-edge threat. Not only are trans...
Nov 2019
Drug
Other Name(s): Unituxin®
Quick Link(s):
Drug Monograph
Jun 2023
Document
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Statistical Reports
This page is for drug manufacturers who need information on the cancer drug submission process. Please do not mail cancer drug submissions to Ontario...
Document
May 2020
Document
May 2020

Pages